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Chemical Genetic Blockade of Transformation Reveals
Dependence on Aberrant Oncogenic Signaling
specificity or to the unexpected role of EGFR in these
processes.
EGFR is a 170 kDa protein defining the erbB family of
Qi-Wen Fan,1,2,3 Chao Zhang,4 Kevan M. Shokat,4
and William A. Weiss1,2,3,5
1Departments of Neurology
2 Pediatrics transmembrane receptor tyrosine kinases, and it plays a
central role in proliferation, differentiation, migration,3 Neurological Surgery and
4 Cellular and Molecular Pharmacology and oncogenesis (reviewed in [4]). The identification of
EGFR as the cellular homolog of the transforming onco-University of California
521 Parnassus Avenue gene v-erbB was one of the first links between an acti-
vated oncogene and the development of cancer [5].San Francisco, California 94143
V-erbB differs from EGFR principally through extensive
deletion of the extracellular domain [6]. This mutation
confers constitutive kinase activity of the receptor [7–9]
Summary and is the only mutation in v-erbB that is required for
transformation of mammalian cells [10]. In humans, ex-
Background: Our understanding of protein kinase inhi- tensive deletions of the extracellular domain of EGFR
bition in the treatment of cancer is clearly limited by the have been identified in astrocytic neoplasms [11–14].
lack of inhibitors that selectively block a single kinase The most common of these alterations, EGFRvIII, is simi-
implicated in neoplastic transformation. One approach lar to v-erbB in that it shows constitutive kinase activity
to developing specific inhibitors is to engineer in protein independent of ligand binding [13, 15, 16].
kinases silent mutations that allow selective inhibition We have developed a model system for studying the
while retaining kinase activity. Because it is implicated cellular response to inhibition of v-erbB in a situation in
in a large number of malignancies, EGFR provides an which the kinase inhibitor is specific for the oncogene.
attractive target for such selective kinase inhibition. We show that specific inhibition of v-erbB leads to nor-
Results: We generated an inhibitor-sensitized allele of malization of cellular morphology and of basal cellular
the transforming receptor tyrosine kinase v-erbB. Trans- signaling through MAP kinase and PI(3) kinase path-
formation of immortalized rodent fibroblasts by sensi- ways. Despite apparently reversing many features of
tized versions of v-erbB (v-erbB-as1) was blocked by transformation, treated cells showed sustained G0 arrest
1-napthyl PP1 (NaPP1), a cell-permeable ATP-competi- and failed to re-enter the cell cycle. These data suggest
tive inhibitor. NaPP1 also reversed morphological trans- that transformed cells become dependent on oncogenic
formation by v-erbB-as1. Signaling through MAP kinase signaling and are subsequently incapable of recovering
and PI(3) kinase was initially blocked by inhibitor treat- normal proliferative functions.
ment and then recovered to levels comparable to those
in nontransformed cells. Surprisingly, NaPP1-treated Results
v-erbB-as1 cells failed to re-enter the cell cycle, showed
decreased levels of D- and A-type cyclins, and showed An Inhibitor Analog-Sensitive Allele of v-erbB
increased levels of p27. To extend this result, we showed Is Highly Transforming
that NaPP1 treatment of v-Src-as1 cells also led to cell Tyrosine kinases share a consensus ATP binding site
cycle arrest. Arrested cells could be rescued with a that can be specifically mutated while kinase activity
conditional allele of Raf or by transduction of a constitu- is retained. This creates a unique pocket that allows
tive allele of cyclin D1. competitive inhibition of ATP binding with compounds
Conclusions: These data suggest that mammalian cells such as NaPP1 [17]. To engineer v-erbB-as1, we muta-
can become dependent on aberrant oncogenic signal- genized T210 to alanine. We subsequently transformed
ing; this dependency renders them incapable of re- NIH3T3 cells with v-erbB or v-erbB-as1 and analyzed the
turning to a normal, proliferative phenotype. level and pattern of tyrosine-phosphorylated proteins in
comparison to the levels of v-erbB. Figure 1A shows that
the level and profile of tyrosine-phosphorylated proteinsIntroduction
was identical in cells transduced with v-erbB and
v-erbB-as1, suggesting that these alleles show similarThe epidermal growth factor receptor (EGFR) is a proto-
kinase activities as well as similar substrate specificities.type receptor tyrosine kinase implicated in tumors of
The cloning efficiency in soft agar was indistinguishablethe brain, lung, breast, head and neck, bladder, skin,
when either v-erbB or v-erbB-as1 was used to transformand ovary [1]. Three quinazoline inhibitors of EGFR have
immortalized rodent fibroblasts (Figure 1B). These ob-been tested in phase 1 and 2 clinical trials. ZD1839
servations argue that transformation by v-erbB-as1 isIressa has a dose-limiting acne-like rash as an associ-
comparable to that of the unmanipulated v-erbB allele.ated toxicity [2]. OSI-774 had dose-limiting toxicities
including folliculitis, diarrhea, and mucositis [3]. These
NaPP1-Treatment Can Block and Reversedose-limiting toxicities are presumably due to a lack of
Transformation by v-erbB-as1
Figure 1B shows that treatment of cells with 2M NaPP1
completely blocked the proliferation of v-erbB-as1-5 Correspondence: weiss@cgl.ucsf.edu
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transduced cells in soft agar. The IC50 for NaPP1-medi-
ated growth inhibition in this assay was between 0.5 and
1M and was consistent with the range of concentration
required to inhibit basal v-erbB-as1 phosphorylation
(Figure 1A).
Mice injected subcutaneously with v-erbB or v-erbB-
as1 cells formed tumors of similar size at similar laten-
cies (Figure 1C). NaPP1 completely blocked tumor for-
mation in 5 of 6 mice that were injected subcutaneously
with v-erbB-as1 cells and subjected to daily intraperito-
neal injections of NaPP1 for 19 days. One of 6 mice in
this cohort showed only partial blockage of tumor
growth and developed a tumor of approximately 20%
the size of untreated controls. Tumors from mice in-
jected with v-erbB cells were unaffected by treatment
with NaPP1 (Figure 1C). These experiments demon-
strated that v-erbB-as1 kinase activity induced tumor
formation and that tumor growth could be blocked by
the selective inhibitor NaPP1.
We next asked whether NaPP1 could reverse pre-
established transformation mediated by v-erbB-as1.
Figure 1A shows that NaPP1 reversed tyrosine phos-
phorylation of v-erbB-as1-transformed cells in a dose-
dependent manner. At 2 M NaPP1, cells transduced
with v-erbB-as1 showed full reduction of overall tyrosine
phosphorylation to the level seen in cells transduced
with empty vector (Figure 1A). There was no detectable
decrease in the phosphorylation of cells transduced with
v-erbB in response to treatment with 2 M NaPP1.
NaPP1 Transiently Blocks Signaling Downstream
from v-erbB and Reverses Morphologic
and Cytoskeletal Abnormalities
Signaling by v-erbB is mediated at least in part through
the activation of MAP kinase/extracellular signal-regu-
lated kinase 1,2 (ERK 1,2) and PI3/Akt kinase pathways
(reviewed in [18]). We therefore examined the status of
these pathways in cells transduced with v-erbB and
v-erbB-as1. Figure 2 demonstrates that phospho-ERK
was undetectable after 3 hr of treatment with NaPP1
and that the levels and cytosolic localization of phos-
pho-ERK return by 24 hr in parallel with normalization
of actin stress fibers. Western blotting with antibodies
against active (phosphorylated) and total ERK and Akt
(Figure 2E) demonstrated that NaPP1 treatment ofFigure 1. Characterization of v-erbB-as1
v-erbB-as1 cells led to transient decreases in the levels(A) Reversal of tyrosine phosphorylation by treatment of NIH3T3
of phospho-ERK and phospho-Akt, which recovered bycells with NaPP1. Vector transduced NIH3T3 cells (lane 1), v-erbB-
24 hr to levels comparable to those in nontransformedtransformed cells (lanes 2 and 3), and v-erbB-as1-transformed cells
(lanes 4–8) were incubated with 1.2% DMSO (lanes 1, 2, and 4) cells (Figure 2J). Levels of total ERK and total Akt were
or with NaPP1 in 1.2% DMSO (lanes 3 and 5–8) at the indicated unchanged.
concentrations. Cells were lysed after 24 hr, and proteins were im-
munoblotted with anti-phosphotyrosine antibody 4G10.
(B and C) NaPP1 treatment blocks proliferation and transformation Inhibition of MAP Kinase but Not Akt Leads
by v-erbB-as1 and has no effect on v-erbB. (B) Soft-agar colonies to Stress Fiber Loss in NIH3T3 Fibroblasts
grown for 2 weeks in varying concentrations of NaPP1 (0–5 M) Expressing v-erbB-as1
were stained and counted. Results represent three independent
To further characterize the morphological changes in-plates per experimental point. (C) Cells transduced with v-erbB or
duced by transformation with v-erbB or v-erbB-as1, wev-erbB-as1 (1  106) were injected subcutaneously in BALB/c nu/
analyzed the actin cytoskeleton by immunofluorescencenu mice on day 0. Animals were treated with a daily intraperitoneal
injection of either 20 mg/kg NaPP1 or vehicle starting on day 1 post- microscopy. Actin stress fibers were clearly reduced
implant. Each data point represents mean tumor volume  S.E. in v-erbB-as1-transformed NIH3T3 as compared with
obtained from six mice. nontransformed controls (Figures 2A and 2D). In re-
sponse to 48 hr NaPP1 treatment, cells transformed with
v-erbB-as1 reverted to a pattern comparable to that of
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Figure 2. Selective Inhibition of v-erbB-as1 Correlates with Morphologic Reversal of Transformation
(A–D) NIH3T3 cells and v-erbB-as1 cells were treated with 2 M NaPP1 for the indicated time periods and incubated with anti-pERK antibody
(green). F-actin was visualized with rhodamine-phalloidin (red), and nuclei were labeled with DAPI (blue). Phospho-ERK was undetectable
after 3 hr of treatment with NaPP1 and returned by 48 hr in parallel with normalization of actin stress fibers.
(E) Cells transduced with v-erbB or v-erbB-as1 were treated with NaPP1 (2 M), harvested at the indicated times, and blotted for total and
phosphorylated ERK and Akt.
(F–I) v-erbB –as1 cells were treated with 1.2% DMSO (F), 2 M NaPP1 (G), 40 M PD 098059 (H), or 20 M LY 294002 (I). Cells were stained
with rhodamine-phalloidin at 48 hr and visualized by confocal laser scanning microscopy.
(J) Vector and v-erbB-as1-transduced cells were incubated with vehicle, 40 M PD098059, 2 M NaPP1, or 20 M LY294002. Cells were
harvested at 6 hr post-treatment, lysed, and immunoblotted for total ERK (tERK), phosphorylated ERK (pERK), and phosphorylated Akt (pAKT).
nontransformed NIH3T3 cells (Figures 2C and 2D). In observations suggest that the rounding up of cells dur-
ing transformation by v-erbB-as1 is more strongly influ-contrast, cells transformed with v-erbB retained a trans-
formed morphology after treatment with NaPP1 (data enced by MAP kinase than by PI(3) kinase.
not shown).
To explore the role of these signaling pathways in NaPP1 Treatment of v-erbB-as1 and v-Src-as1
Cells Leads to G0-G1 Arrestmorphological transformation, v-erbB-as1 cells were
treated with the monospecific v-erbB-as1 inhibitor In response to NaPP1, fibroblasts transformed by
v-erbB-as1 showed morphological reversal of transfor-NaPP1, with LY294002 (a relatively selective inhibitor
of PI(3) kinase [19, 20]), or with PD098509, a relatively mation and recovery of basal signaling through MAP
kinase and PI(3) kinase. Surprisingly however, theseselective inhibitor of MEK1 [21]. PD098509 restored lev-
els of actin stress fibers in a manner comparable to cells did not proliferate, even after 48 hr when the activi-
ties of mitogenic kinases were restored (Figure 2). CellsNaPP1 (Figures 2G and 2H). In contrast, LY294002, at
a dose sufficient for inhibiting Akt activity (Figure 2J), transformed with v-erbB-as1 accumulated in G0-G1
phase of the cell cycle after 24 hr of exposure to NaPP1,showed no effect on actin stress fibers (Figure 2I). These
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cells with v-erbB-as1 and added NaPP1 at 0, 3, 6, 12,
24, and 48 hr after transduction. Puromycin was added
at 48 hr, and puromycin-resistant cells were counted at
day 10. Addition of NaPP1 up to 12 hr after transduction
of v-erbB-as1 had no effect on proliferation, whereas
addition of NaPP1 at 24 hr and at later points resulted
in proliferation arrest (our unpublished data).
This proliferation arrest was surprising because nor-
mal 3T3 cells proliferate in the absence of v-erbB-as1.
One would therefore predict that NaPP1-treated v-erbB-
as1 cells should behave like normal 3T3 cells and con-
tinue to proliferate. If v-erbB-as1 heterodimerized with
a growth factor receptor required for basal growth, then
NaPP1 treatment of this heterodimer could lead to
growth arrest. This scenario is unlikely because signal-
ing through MAP kinase and PI(3) kinase pathways re-
covers after NaPP1 treatment, and such recovery should
not occur if a growth factor receptor required for basal
growth were blocked. Nevertheless, to address this con-
cern further, we transduced retroviruses containing
v-erbB or v-erbB-as1 into 3T3 cells grown continually
in the presence of 2 M NaPP1 such that the v-erbB-
as1-transforming kinase was continuously inhibited. Pu-
romycin-resistant v-erbB-as1 clones were readily se-
lected from cells grown and transduced in the presence
of NaPP1 (Figure 3B), suggesting that growth arrest was
not secondary to a dominant-negative effect of NaPP1
in a v-erbB-as1 background.
To determine whether cell cycle arrest could be a
general response to kinase inhibitor therapy, we per-
formed flow-cytometric analysis of NIH3T3 cells trans-
formed with v-Src-as1 [22]. NaPP1 treatment of v-Src-
as1 cells again resulted in arrest at the G0-G1 check
point, with blockade of v-Src-as1 kinase activity similar
to that seen with v-erbB-as1 (Figure 4). Unlike v-erbB,
v-Src is thought to signal as a monomer (reviewed in
[23]). Therefore, heterodimerization with other Src family
members is not a likely mechanism by which NaPP1
treatment of v-Src cells could block progression through
the cell cycle. In additional experiments (see Supple-
mentary Material available with this article online), we
also demonstrated that PDGF was sufficient to support
growth of v-erbB-as1 cells in low serum and that cell
cycle arrest mediated by NaPP1 treatment of these cells
occurred through a PDGF-independent pathway.
Figure 3. Reversibly Transformed v-erbB-as1 Cells Recover Normal Decreased Levels of D and A Type Cyclins
Signaling but Remain Arrested in G0/G1 and Increased Levels of p27 in NaPP1-Treated
(A) Equal numbers of cells were transduced as indicated and grown
v-erbB-as1 Cellsat subconfluence in 2 M NaPP1 or in 1.2% DMSO. Cells were
Cyclins are required for progression through the cellharvested at 48 hr and analyzed by flow cytometry.
cycle (reviewed in [24]). If levels of cyclins were low or(B) To rule out a dominant-negative cause of growth arrest, cells
were grown in the absence or presence of NaPP1 (2 M) and subse- if levels of cyclin-dependent kinase inhibitors were high
quently transduced with retroviral vectors carrying v-erbB or v-erbB- in NaPP1-treated v-erbB-as1 cells, then these cells
as1. Results represent the mean of three 6-well plates per experi- would be unable to progress through the cell cycle. To
mental point.
address the state of cyclins and the cyclin-dependent
kinase inhibitor p27 in NaPP1-treated v-erbB-as1 cells,
we performed Western blotting against cyclins A, D1,and did not re-enter S phase during a 48 hr observation
period (Figure 3). In contrast, G0-G1 arrest was not ob- and D2 and against p27 (Figure 5). These experiments
demonstrated that NaPP1-treated v-erbB-as1 cellsserved in NaPP1-treated cells transduced with empty
vector or with v-erbB cells (Figure 3). were quiescent at least in part because all three cyclins
were reduced and because levels of p27 in the sameTo distinguish the requirement for v-erbB in the initia-
tion and maintenance of transformation, we transduced cells were high. The low level of D type cyclins (and in
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Figure 5. G0 Arrest in v-erbB-as1-Transduced Cells after Treatment
with NaPP1
Cells were transduced as indicated, grown to subconfluence,
treated with NaPP1 for 48 hr, and immunoblotted.
arrest in NaPP1-treated v-erbB-as1 cells results from
low levels of cyclin D1.
The G0-G1 arrest observed after NaPP1 treatment of
v-erbB-as1 or v-Src-as1 cells suggests that reversal of
an initiating oncogenic event by drug treatment was
insufficient to allow reentry into the cell cycle. To better
characterize the mechanism of cell cycle arrest, we
asked whether proliferation could be restored with a
conditional allele of Raf. We transduced cells with
v-erbB-as1 or v-Src-as1 and with Raf1-ER, a fusion
protein of the kinase domain of Raf-1 with the hormone
binding domain of the human estrogen receptor, and
EGFP [28]. NaPP1-mediated blockade of v-erbB-as1
resulted in growth arrest that could be rescued by
subsequent hydroxytamoxifen-mediated activation of
Figure 4. NaPP1 Treatment of Cells Transformed by v-Src-as1 Also
Raf1-ER (Figure 7). Identical results were observed inResults in Cell Cycle Arrest
NaPP1-arrested v-Src-as1 cells (our unpublished data).(A) NIH3T3 cells transduced with v-Src or v-Src-as1 were incubated
with 1 M NaPP1 for 0, 6, 24, and 48 hr, labeled with BrDU, and
analyzed by flow cytometry. Discussion
(B) A portion of cells from (A) were harvested and immunoblotted
with 4G10. An Allele of v-erbB Shows Specific Inhibition
by a Selective Inhibitor
We used a chemical genetic strategy to generate alleles
particular the absence of cyclin D1) in cells transduced of v-erbB that could be selectively inhibited by cell-
with v-erbB-as1 and treated with NaPP1 argues that permeable ATP-competitive inhibitors. The v-erbB-as1
these cells are arrested in a G0 rather than a G1 state. (T210A) mutant showed transformation efficiencies and
Others have observed high levels of p27 in response patterns and levels of cellular phosphotyrosine that were
to treating cells with inhibitors of EGFR [25, 26]. The indistinguishable from those of the parental v-erbB allele
reduction in cyclin D1/Cdk4 complexes presumably (Figure 1). Injection of v-erbB- or v-erbB-as1-transduced
leads to increased free p27, which binds and inactivates NIH3T3 cells into immunocompromised mice led to tu-
Cdk2 and thereby blocks its ability to phosphorylate mor formation with comparable latencies. These three
and degrade p27 [27]. experiments argue that the transforming potentials of
To rule out the possibility that low levels of cyclin v-erbB and v-erbB-as1 are functionally equivalent.
D1 were the result of cell cycle phase differences, we Treatment of transduced 3T3 or Rat1a cells with
incubated v-erbB-as1 cells with antisera to cyclin D1 NaPP1 blocked transformation by v-erbB-as1 and had
and visualized these by confocal microscopy. Figures no demonstrable effect on v-erbB. Treatment of mice
6A and 6B show that nuclear cyclin D1 levels were re- injected with these cells similarly impacted v-erbB-as1
duced dramatically by NaPP1 treatment. We next trans- with no effect on v-erbB. These data demonstrate that
duced cyclin D1 into v-erbB-as1 cells. NaPP1 treatment NaPP1 selectively inhibited v-erbB-as1 but had no
of these cells did not arrest proliferation, nor did it impact discernable effect on signaling mediated by v-erbB. Im-
portantly, NaPP1 could also reverse both tyrsosinecyclin D1 levels. These experiments argue that cell cycle
An Inhibitor Analog-Sensitive Allele of v-erbB
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Figure 6. Rescue of Proliferation Arrest by
Cyclin D1
v-erbB-as1 cells were transduced with cyclin
D1 and incubated with 2 M NaPP1.
(A–D) Cells were incubated with antisera to
cyclin D1 (red), counterstained with To-Pro-
3 iodide, and visualized by confocal micros-
copy. Pink color in overlay indicates nuclear
localization of cyclin D1. NaPP1 treatment of
v-erbB-as1 cells leads to reduction of D1 (Fig-
ure 6B), which was not observed in v-erbB-
as1 cells transduced with cyclin D1.
(E and F) BrDU-labeled v-erbB-as1 cells or v-
erbB-as1/D1 cells were either untreated or
treated with NaPP1 (2 M). Aliquots of cells
were analyzed for cyclin D1 or 4G10 (E), and
three replicates were analyzed by flow cy-
tometry (F).
phosphorylation and the transformed morphology asso- cycle arrest in NaPP1-treated v-erbB-as1 cells, we dem-
onstrated that NaPP1 had no impact on vector-trans-ciated with v-erbB-as1 transduction of 3T3 cells (Fig-
ure 2). formed cells, that NaPP1 treatment did not affect the
transduction of v-erbB-as1, and that NaPP1 treatment of
v-Src-as1 also caused proliferation arrest. Additionally,G0 Arrest in Reversibly Transformed Cells
PDGF efficiently supported growth of serum-starvedSuggests that Cells Become Dependent on Aberrant
v-erbB-as1 cells, and signaling through the PDGF recep-Oncogenic Signaling
tor was intact in these cells even after NaPP1 treatmentAfter treatment with NaPP1, transformed v-erbB-as1
arrested their growth. These data collectively argue thatcells showed reduced signaling through MAP kinase
G0 arrest observed after NaPP1 treatment of cells trans-and PI(3) kinase, with subsequent recovery of basal mi-
formed with either v-erbB-as1 or v-Src-as1 reflects thetogenic signaling through both pathways. Despite the
cells’ dependence on aberrant signaling by the trans-apparent normalization of morphology and signaling in
forming oncogene and that reversal of the initiating on-these cells, NaPP1 treatment of cells transduced with
cogenic event by drug treatment was insufficient tov-erbB-as1 led to G0 arrest, with reduced levels of D
allow re-entry into the cell cycle.and A type cyclins and high levels of p27. Similar block-
We hypothesize that NaPP1-treated v-erbB-as1 andade and subsequent recovery of MAP kinase signaling
v-Src-as1 cells failed to proliferate because some as-has been described in cells made quiescent (in G0) by
pect of signaling has not been restored in these cells.growth in low serum [29]. Quiescence in serum-starved
Further examination of reversible transformation in thiscells was associated with cytoplasmic sequestration of
simple v-erbB-as1-driven system should allow us tophosphorylated ERK, as well as with recovery of prolifer-
identify the critical determinants that underlie cell cycleation upon addition of serum to the media [29]. Our
arrest in response to NaPP1 treatment. In two experi-results with NaPP1-treated v-erbB-as1 cells demon-
ments aimed at understanding the mechanism of cellstrate that phospho-ERK was distributed in the cyto-
cycle arrest in this system, we have shown that bothplasm and nucleus (Figure 3), suggesting that cyto-
cyclin D1 and Raf restored proliferation in NaPP1-plasmic sequestration did not play a major role in the
treated v-erbB-as1 cells (Figures 6 and 7). These obser-G0 arrest observed in these cells.
To exclude a dominant-negative mechanism of cell vations suggest the block in cell cycle signaling lies
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that other molecularly targeted agents may have similar
efficacy. EGFR is an obvious candidate for kinase inhibi-
tor therapy because it is implicated in a broad range
of malignancies. Because most commonly used kinase
inhibitors (including the new EGFR inhibitors now in clini-
cal trials) also inhibit endogenous signaling pathways,
one cannot differentiate between true oncogene-depen-
dent events (such as those mediated by v-erbB) and the
similar normal pathways (mediated through EGFR and
other cellular kinases). By using analog-selective alleles
of v-erbB and v-Src, as well as monoselective inhibitors
of these alleles, we selectively blocked oncogenic sig-
naling and could accurately distinguish normal from ab-
errant signaling.
Using this approach, we showed that cells adapted
rapidly to oncogenic signaling prior to the acquisition of
secondary mutations in additional oncogenes or tumor
suppressor genes. This adaptation shifted cells from
normal growth factor control to oncogene-dependent
growth. Others have shown that tumor growth in trans-
genic mice required continued signaling by the initiating
oncogene [31–34]. We here extend and in part explain
these observations by showing that the original onco-
gene has really co-opted the cell signaling machinery.
This adaptation happened on an extremely fast time
scale and explains the continued dependence on signal-
ing by the initiated oncogene (i.e., the cell has become
addicted to the aberrant oncogenic signaling [35]).
Our observations in rodent fibroblasts may help to
explain the remarkable therapeutic index associated
with Gleevec, a drug for which the maximum tolerated
Figure 7. Activation of GFPRaf1-ER Rescues NaPP1-Mediated G0 dose in human patients has still not been reached [36].
arrest Gleevec’s lack of overt toxicity is somewhat surprising
NIH3T3 cells were transduced with v-erbB-as1 and GFPRaf1-ER. because it is not selective for the BCR-ABL gene product
Cells were untreated (A), treated with 15 nM 4-hydroxytamoxifen specific to chronic myelogenous leukemia (CML) but
(4-HT) for 48 hr (B), or treated with 2 M NaPP1 in the absence (C)
also blocks c-Abl, c-Kit (stem cell factor), and PDGFRor presence (D) of 4-HT. Rhodamine-phalloidin-stained cells were
[37]. If BCR-Abl has co-opted the signaling machineryvisualized by confocal laser scanning microscopy. Green signal is
of CML cells, then one could achieve cell cycle arrestfrom the EGFP epitope on the Raf-1-ER chimera. (E and F) BrDU-
labeled cells were either untreated or treated with NaPP1 (2M) plus even through partial inhibition of BCR-Abl by using a
25 nM 4-HT for 48 hr as indicated. Aliquots of cells were analyzed for dose of Gleevec that does not impact basal signaling in
indicated cell cycle proteins (E), and three replicates were analyzed normal cells. By analogy, our data suggest that selective
by flow cytometry (F).
inhibition of EGFR may effectively block proliferation of
cancer cells in vitro. It is likely that normal cells will
between the growth factor receptor and Raf. Of course, require higher levels of EGFR inhibition to block basal
it is possible that supraphysiological activation of the signaling and that the therapeutic index for EGFR inhibi-
conditional Raf allele could overwhelm the cell cycle tors may be favorable.
signaling machinery and override a block in cell signaling As new kinase inhibitors become available in the clini-
downstream of Raf. Experiments are currently in prog- cal treatment of patients with cancer, it becomes in-
ress to distinguish between these possibilities. creasingly important to understand the effect of selec-
Interestingly, others have used a modestly selective tively inhibiting specific kinases. This chemical genetic
EGFR inhibitor (AG-1478) to treat breast and embryonal strategy can help to achieve an improved understanding
cancer cell lines and have also observed growth arrest of selective inhibition and can provide information that
[27, 30]. The full extent of molecular lesions contributing will help distinguish specific from nonspecific effects
to transformation in these human cell lines remains un- associated with nearly all kinase inhibitors now being
known. In addition, the spectrum of intracellular kinases used in or being developed for clinical applications.
impacted by AG-1478 could be broad. Nevertheless, the
observation that inhibition of EGFR in human cancer cell Experimental Procedures
lines also led to growth arrest argues that this may be
Construction of Analog-Sensitive Alleles of v-erbBa general phenomenon.
Overlap extension PCR [38] with Expand high-fidelity polymerase
(Roche, Indianapolis, IN) was used for making analog-sensitive al-Conclusions
leles of the ES-4 allele of v-erbB. Four synthetic oligonucleotides
were used for generation of v-erbB-as1.
The remarkable efficacy of Gleevec in the treatment of Primers were as follows: primer 1, 5-CTGCAGAACCAATGCATT
GGCTGGCTCGAGGGTGGATCA-3; primer 2, 5-GCATAAGCTGGGchronic myelogenous leukemia has raised expectations
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